Sees 2026 adjusted EBITDA $105M-$110M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- AORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Artivion: Positive Clinical Data and Pipeline Progress Support Sustained Growth and Buy Rating
- Artivion announces presentations of clinical data from Nexus and AMD trials
- Artivion: Strategic Growth, Market Expansion, and Long-Term Value Creation Drive Buy Rating